+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A potential novel therapeutic addition to statin therapy for dyslipidemia

A potential novel therapeutic addition to statin therapy for dyslipidemia

Current Atherosclerosis Reports 13(1): 9-11

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 051215453

Download citation: RISBibTeXText

PMID: 21053106

DOI: 10.1007/s11883-010-0144-1

Related references

Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: The dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study. Indian Heart Journal 68(5): 646-654, 2016

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. Journal of Lipid Research 56(12): 2381-2392, 2015

Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET). Internal Medicine 50(12): 1273-1278, 2011

Addition of ezetimibe to ongoing statin therapy Incremental reduction in low-density lipoprotein cholesterol is independent of statin type. European Heart Journal 23(Abstract Suppl.): 19, August-September, 2002

Vardenafil in men with stable statin therapy and dyslipidemia. Journal of Sexual Medicine 5(6): 1455-1467, 2008

Statin therapy for the treatment of diabetic dyslipidemia. Diabetes/Metabolism Research and Reviews 19(4): 280-287, 2003

Managing diabetic dyslipidemia: beyond statin therapy. Current Diabetes Reports 9(1): 11-17, 2009

Managing the dyslipidemia of metabolic syndrome: beyond statin therapy. Metabolic Syndrome and Related Disorders 10(3): 159-160, 2012

Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?. International Journal of Cardiology 110(2): 276-277, 2006

The dyslipidemia of chronic renal disease: effects of statin therapy. Current Opinion in Lipidology 17(6): 659-666, 2006

Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Current Atherosclerosis Reports 7(1): 29-33, 2005

Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Canadian Journal of Cardiology 26(9): E330, 2010

Correlates of Achieving Statin Therapy Goals in Children and Adolescents with Dyslipidemia. Journal of Pediatrics 178: 149-155.E9, 2016

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study. Vascular Health and Risk Management 10: 225-235, 2014

Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis. International Journal of Cardiology 222: 119-129, 2016